BioSpecifics Technologies Corp (BSTC) News
Filter BSTC News Items
BSTC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest BSTC News From Around the Web
Below are the latest news stories about Biospecifics Technologies Corp that investors may wish to consider to help them evaluate BSTC as an investment opportunity.
BioSpecifics Technologies Corp. (BSTC) Investor Presentation - SlideshowThe following slide deck was published by BioSpecifics Technologies Corp. in conjunction with this event.... |
BioSpecifics to Present at the Virtual Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech SummitWILMINGTON, Del., Sept. 14, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today… |
The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In SeptemberScaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Allovir Inc (NASDAQ: ALVR ) BioLife Solutions Inc (NASDAQ: BLFS ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (reacted to second-quarter results) CymaBay Therapeutics Inc (NASDAQ: CBAY ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Fulgent Genetics Inc (NASDAQ: FLGT ) Harvard Bioscience, Inc. (NASDAQ: HBIO ) Inari Medical Inc (NASDAQ: NARI ) Kura Oncology Inc (NASDAQ: KURA ) Omeros Corporation (NASDAQ: OMER ) ( announced positive results for the study of its lead asset in COVID-19) Pacira Biosciences Inc (NASDAQ: PCRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Rocket Pharmaceuticals Inc (NASDAQ: RCKT ) Seres Therapeutics Inc (NASDAQ: MCRB ) ( reacted to positive late-stage clinical r... |
BioSpecifics Reports Second Quarter 2020 Financial and Operating ResultsWILMINGTON, Del., Aug. 10, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North America, today… |
BioSpecifics Technologies: Microcap At Inflection Point Has Upside PotentialInvestment Thesis BioSpecifics Technologies Corp. 5-year share price performance. Source: TradingView BioSpecifics (BSTC) is a small microcap with a market cap of just $474m and revenues of $38.1m in 2019, but the company is entering an exciting phase in its development with the recent FDA approval of its injectable collagenase... |
BioSpecifics Appoints Alex Monteith as Chief Business OfficerWILMINGTON, Del., July 20, 2020 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC) (the "Company"), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first-in-class collagenase-based product marketed as XIAFLEX® in North… |
Chugoku Electric Power Company, Inc. (The) -- Moody's announces completion of a periodic review of ratings of Chugoku Electric Power Company, Inc. (The)Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Chugoku Electric Power Company, Inc. (The) and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. |
Do BioSpecifics Technologies's (NASDAQ:BSTC) Earnings Warrant Your Attention?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to... |
The Daily Biotech Pulse: Intersect ENT Jumps On M&A Speculation, VIVUS Files For BankruptcyHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) AbbVie Inc (NYSE: ABBV ) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Akero Therapeutics Inc (NASDAQ: AKRO ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) argenx SE – ADR (NASDAQ: ARGX ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Biondvax Pharmaceuticals Ltd – ADR (NASDAQ: BVXV ) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) (FDA approved the cellulitis drug it had licensed to Endo International PLC (NASDAQ: ENDP )) Cerus Corporation (NASDAQ: CERS ) (announced study results demonstrating that its INTERCEPT Blood System inactivates SARS-CoV-2 in plasma components intended for transfusion) Corvus Pharma... |
The Week Ahead In Biotech: Endo, Eagle Pharma FDA Decisions, ObsEva Late-Stage Readouts In FocusBiotech stocks rebounded in the holiday-shortened week ending July 2 as investors reacted to pending clinical trial readouts and the news flow surrounding COVID-19 vaccine and treatment development. Australian biopharma Alterity Therapeutics Ltd (NASDAQ: ATHE) was among the biggest gainers of the week after the company said it received FDA guidance for the Phase 2 study for its Parkinsonian disorder drug.Inovio Pharmaceuticals Inc (NASDAQ: INO) and Pfizer Inc. (NYSE: PFE)/ BioNTech SE - ADR (NASDAQ: BNTX) were among the companies that issued updates on their coronavirus vaccine programs. The week also saw FDA issuing guidance on the approval of COVID-19 vaccines, with the agency suggesting a vaccine needs to demonstrate at least 50% efficacy in a placebo-controlled trial.The following... |